-
公开(公告)号:US20250002855A1
公开(公告)日:2025-01-02
申请号:US18886331
申请日:2024-09-16
Applicant: Immatics US, Inc.
Inventor: Melinda MATA , Mamta KALRA , Ali MOHAMED , Steffen WALTER , Yannick BULLIARD
IPC: C12N5/0783 , A61K39/00 , C07K14/725
Abstract: An in vitro method of expanding γδ T cells includes isolating γδ T cells from a blood sample of a human subject, activating the isolated γδ T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated γδ T cells, and optionally restimulating the expanded γδ T cells.
-
公开(公告)号:US20210285011A1
公开(公告)日:2021-09-16
申请号:US17197927
申请日:2021-03-10
Applicant: Immatics US, Inc.
Inventor: Melinda MATA , Mamta KALRA , Yannick BULLIARD , Steffen WALTER , Ali MOHAMED
IPC: C12N15/86 , C12N15/10 , C07K14/725 , C12N15/113
Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
-
公开(公告)号:US20200297768A1
公开(公告)日:2020-09-24
申请号:US16823987
申请日:2020-03-19
Applicant: IMMATICS US, INC.
Inventor: Amir ALPERT , Mamta KALRA
IPC: A61K35/17 , A61P35/00 , C12N15/86 , C12N5/0783
Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.
-
公开(公告)号:US20250034588A1
公开(公告)日:2025-01-30
申请号:US18897063
申请日:2024-09-26
Applicant: Immatics US, Inc.
Inventor: Mamta KALRA , Agathe BOURGOGNE , Ali MOHAMED , Steffen WALTER
Abstract: The present disclosure relates to T cells transduced with a viral vector at a volumetric concentration for immunotherapy and methods thereof. In another aspect, the present disclosure relates to the assessment of optimal lentiviral vector concentrations for transducing T cells. The present disclosure further provides for T cell populations produced by methods described herein.
-
5.
公开(公告)号:US20230348548A1
公开(公告)日:2023-11-02
申请号:US18309080
申请日:2023-04-28
Applicant: IMMATICS US, INC.
Inventor: Justin GUNESCH , Mohammad HOSSAIN , Gagan BAJWA , Melinda MATA , Mamta KALRA
IPC: C12N5/0783 , C12N15/86 , C07K14/705 , C07K16/00 , C07K14/54 , C07K14/725 , A61K39/00 , A61K39/39
CPC classification number: C07K14/5443 , A61K39/39 , A61K39/4611 , A61K39/4613 , A61K39/4621 , A61K39/4632 , A61K39/4633 , A61K39/4635 , A61K39/4643 , C07K14/7051 , C07K14/70517 , C07K16/00 , C12N5/0636 , C12N15/86 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55533 , A61K2039/55538 , A61K2039/55561 , A61K2039/55588 , C12N2502/1121 , C12N2740/15043
Abstract: The present disclosure relates to cells capable of co-expressing T cell receptors (“TCR”) together with membrane-bound IL-15 polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified IL-15, IL-15Rα, IL-15/IL-15Rα fusion polypeptide, and IL-15Rα/IL-15 fusion polypeptide sequences, vectors, and associated methods of making and using the same. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods of making and using the same.
-
公开(公告)号:US20220202862A1
公开(公告)日:2022-06-30
申请号:US17563599
申请日:2021-12-28
Applicant: Immatics US, Inc.
Inventor: Gagan BAJWA , Mamta KALRA , Melinda MATA
IPC: A61K35/17 , C12N15/86 , C12N5/0783 , C07K14/725 , C07K14/705
Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for modified CD8 sequences, vectors, and associated methods thereof.
-
公开(公告)号:US20250075230A1
公开(公告)日:2025-03-06
申请号:US18824203
申请日:2024-09-04
Applicant: Immatics US, Inc.
Inventor: Melinda MATA , Mamta KALRA , Yannick BULLIARD , Steffen WALTER , Ali MOHAMED
IPC: C12N15/86 , A61K39/00 , C07K14/725 , C12N5/0783 , C12N15/10 , C12N15/113
Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
-
公开(公告)号:US20250051418A1
公开(公告)日:2025-02-13
申请号:US18590008
申请日:2024-02-28
Applicant: Immatics US, Inc.
Inventor: Melinda MATA , Yannick BULLIARD , Mamta KALRA
IPC: C07K14/705 , A61K39/00 , C07K14/725 , C12N5/078 , C12N5/0783 , C12N15/64 , C12N15/86
Abstract: A vector containing a first nucleotide sequence S1 encoding a protein Z1, a second nucleotide sequence S2 encoding a protein Z2, a third nucleotide sequence S3 encoding a protein Y1, and a fourth nucleotide sequence S4 encoding a protein Y2, in which Z1 and Z2 form a first dimer and Y1 and Y2 form a second dimer, in which the first dimer Z1Z2 is different from the second dimer Y1Y2.
-
9.
公开(公告)号:US20240066127A1
公开(公告)日:2024-02-29
申请号:US18308427
申请日:2023-04-27
Applicant: IMMATICS US, INC.
Inventor: Justin GUNESCH , Melinda MATA , Mamta KALRA , Gagan BAJWA
IPC: A61K39/00 , A61K39/39 , A61P35/00 , C07K14/54 , C07K14/705 , C07K14/725
CPC classification number: A61K39/4635 , A61K39/39 , A61K39/4611 , A61K39/4613 , A61K39/4632 , A61K39/464489 , A61P35/00 , C07K14/54 , C07K14/5434 , C07K14/5443 , C07K14/7051 , C07K14/70517 , A61K2039/55511 , A61K2039/55516 , A61K2039/55522 , A61K2039/55527 , A61K2039/55533 , A61K2039/55538 , A61K2039/55561
Abstract: The present disclosure relates to cells capable of co-expressing one or any combination of T cell receptors (“TCR”), CD8 polypeptides, interleukin 12 (IL-12) polypeptides, interleukin 15 (IL-15) polypeptides, and/or interleukin 18 (IL-18) polypeptides, and the use thereof in adoptive cellular therapy (“ACT”). The present disclosure further provides for modified CD8 sequences, IL-12 sequences, IL-15 sequences, IL-18 sequences, vectors, compositions, transformed T cells, and associated methods thereof.
-
公开(公告)号:US20240150790A1
公开(公告)日:2024-05-09
申请号:US18501269
申请日:2023-11-03
Applicant: Immatics US, Inc.
Inventor: Melinda MATA , Mamta KALRA , Yannick BULLIARD , Steffen WALTER , Ali MOHAMED
IPC: C12N15/86 , C07K14/725 , C12N15/10 , C12N15/113
CPC classification number: C12N15/86 , C07K14/7051 , C12N15/102 , C12N15/113 , C12N2830/48
Abstract: The present invention provides a mutated woodchuck post-transcriptional regulatory element (WPRE). In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.
-
-
-
-
-
-
-
-
-